Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Investors to sell pharmaceutical services firm Seqens to SK Capital

by Rick Mullin
September 2, 2021 | A version of this story appeared in Volume 99, Issue 32
Advertisement

Most Popular in Business

 

A photo of people touring a chemical facility.
Credit: Seqens
French president Emmanuel Macron (right) toured Seqens's facility in Villeneuve-la-Garenne, France, last year.

The investment firm Eurazeo says it will sell its majority stake in Seqens, a French contract development and manufacturing organization (CDMO), to a group of funds led by the investment firm SK Capital Partners. Seqens has acquired several competitors in recent years—including Chemie Uetikon, PCAS, and PCI Synthesis—and now has annual sales of about $1 billion and 3,000 employees. Eurazeo suggests in a press statement that Seqens may be merged with Wavelength Pharmaceuticals, an Israeli CDMO that SK Capital acquired in 2017.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society

You might also like...

Serving the chemical, life science, and laboratory worlds
Pharma services firm Ardena changes private equity hands
SK Capital re-ups investment in Archroma
Fine Industries sold to Chinese buyer

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE